Viekirax: Phase II data

Top-line data from the Japanese Phase III GIFT-1 trial in 363 patients with chronic HCV genotype 1b infection showed that ombitasvir/paritaprevir/ritonavir for 12 weeks led to an SVR 12 weeks

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE